This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Papageorgiou SG, Castelton A, Bloor A, Kottaridis PD . Allogeneic stem cell transplantation as treatment for myelofibrosis. Bone Marrow Transplant 2006; 38: 721–727.
Kröger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornhäuser M et al. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol 2007; 35: 1719–1722.
Cervantes F, Rovira M, Urbano-Ispizua A, Rozman M, Carreras E, Montserrat E . Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant 2000; 26: 697–699.
Koren-Michowitz M, Shimoni A, Vivante A, Trakhtenbrot L, Rechavi G, Amariglio N et al. A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD). Leuk Res 2008; 32: 421–427.
Talarico L, Wolf BC, Kumar A, Weintraub LR . Reversal of bone marrow fibrosis and subsequent development of polycythemia in patients with myeloproliferative disorders. Am J Hematol 1989; 30: 248–253.
Shimoni A, Nagler A . Non-myeloablative stem cell transplantation (NST): chimerism testing as guidance for immune-therapeutic manipulations. Leukemia 2001; 15: 1967–1975.
Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Cross Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162–2168.
Kröger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhäuser M et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007; 109: 1316–1321.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Benjamini, O., Koren-Michowitz, M., Amariglio, N. et al. Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. Leukemia 22, 1961–1963 (2008). https://doi.org/10.1038/leu.2008.215
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.215
This article is cited by
-
What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?
Current Hematologic Malignancy Reports (2015)
-
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study
Leukemia (2013)
-
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation
Bone Marrow Transplantation (2010)
-
Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis
Current Hematologic Malignancy Reports (2010)